Results 111 to 120 of about 284,051 (203)

Treatmen of Familial Hypercholesterolemia

, 2017
Familial Hypercholesterolemia (FH) is a genetic disorder that affect lipoprotein metabolism, which leads to premature CVD , thus its treatment in early ages are highly importanthbkáltalános orvosangolegységes ...
Arkan, Abdollah
core  

Evaluation of Genome in Early Familial Coronary Artery Disease: A Case Report

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2019
Background and Objectives: Coronary artery diseases (CAD) are the most common cause of death in Iran and worldwide. Myocardial infarction (MI) is a complex multifactorial and the most severe type of CAD.
Mohammad Javad Ghorbani, Nematollah Razmi, Seyed Mohammad Bagher Tabei, Mohammad Javad Zibaeenezhad, Hamid Reza Goodarzi   +4 more
doaj  

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients. [PDF]

Front Cardiovasc Med, 2023
Matta A, Rabès JP, Taraszkiewicz D, Carrié D, Roncalli J, Ferrières J.   +5 more
europepmc   +1 more source

Compound Heterozygous Familial Hypercholesterolemia Detected by Cascade Screening

This report outlines the case of a 13-year-old non-Hispanic White male diagnosed with compound heterozygous Familial Hypercholesterolemia (FH) with a biallelic mutation in the LDLR gene.
Hamilton, Luke, Wilson, Don, Nagaram, Sumedha   +2 more
core  

Simvastatin (mk 733) in Heterozygous Familial Hypercholesterolemia - a 2-year Trial

, 1989
Simvastatin (MK 733), a new competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, given in daily doses of 20 mg and 40 mg for 104 weeks, has been shown to lower the serum total cholesterol and low density lipoprotein cholesterol level
Harvengt, C., Leclercq, V.
core  

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease. [PDF]

JACC Case Rep, 2022
Weintraub SF, Schillow JA, Azari BM, Hirsh BJ.   +3 more
europepmc   +1 more source

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia. [PDF]

Atheroscler Plus, 2022
Ferrières J, Farnier M, Bruckert E, Vimont A, Durlach V, Ferrari E, Gallo A, Boccara F, Ferrières D, Béliard S, French FH Registry group: French REgistry of Familial hypERCHOLesterolemia (REFERCHOL).   +10 more
europepmc   +1 more source

Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia

International audienceExtreme elevations in lipoprotein(a) [Lp(a)] and familial hypercholesterolemia (FH) are both monogenic diseases associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD).
Brunham, Liam, Gallo, Antonio, Béliard, Sophie, Cariou, Bertrand, Guay, Simon-Pierre, Paquette, Martine, Baass, Alexis   +6 more
core   +1 more source

Whole Exome Sequencing Insufficient for a Definitive Diagnosis of a Patient with Compound Heterozygous Familial Hypercholesterolemia. [PDF]

Intern Med, 2022
Okada H, Tada H, Nomura A, Nohara A, Okeie K, Nozue T, Michishita I, Takamura M, Takemura H, Kawashiri MA.   +9 more
europepmc   +1 more source

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia. [PDF]

Atheroscler Plus
Tada H, Takeji Y, Takamura M.
europepmc   +1 more source